Preventive migraine treatment in mitochondrial diseases: a case report of erenumab efficacy and literature review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36097203/
Migraine is a common condition in mitochondrial diseases, with a higher prevalence than in the general population. Although several clinical studies support the hypothesis that mitochondrial dysfunction plays a central role in the pathophysiology of migraine, currently there are few data in the lite ...
Conclusion/Relevance: Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) or against its receptor are innovative and specific therapies for migraine prophylaxis. This class of drugs is particularly suitable for subjects, such as those suffering from genetically determined mitochondrial dysfunction, in which pharmacological management can represent a challenge due to the nature of these neurogenetic disorders and/or the frequently associated comorbidities.
-
Huma Sheikh, CEO, NY Neurology Medicine, PCSeptember 28, 2022I was not aware of this connection.